Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 12, 1998, Pages 889-895

  Ohmura, Chie ^a   Tanaka, Yasushi ^a   Mitsuhashi, Naomi ^a   Atsum, Yoshihito ^b   Matsuoka, Kenpei ^b   Onuma, Tomio ^a   Kawamori, Ryuzo ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

Japanese; Metformin; Monotherapy; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGASTRIC PAIN; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; JAPAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0032426327     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85054-6     Document Type: Article

References (14)

1. Stumvoll M, Nurjahan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. NEJM. 1995;333:550-554.
2. DeFronzo RA, Barzilai N, Simomson DC. Mechanism of metformin action in obese and lean noninsulin dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
3. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanism of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43:920-928.
4. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM. 1995;333:541-549.
5. McIntyre HD, Ma A, Bird DM, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust New Zealand J Med. 1991;21:714-719.
6. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metabol. 1994;20:146-149.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. United Kingdom prospective study 13: Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
8. Hermann LS, Schersten B, Melander A. Antihyperglycemic efficacy, response prediction and dose-response relations of treatment with metformin and sulfonylurea, alone and in primary combination. Diabetic Med. 1994;11:953-960.
9. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102:491-497.
10. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 1993;16:621-629.
11. Grant PJ. The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-66.
12. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes. 1995;44:1249-1258.
13. UK Prospective Diabetic Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
14. Tanaka Y, Iwamoto H, Onuma T, et al. Inhibitory effect of metformin on formation of advanced glycation end products. Curr Ther Res. 1997;58:693-697.